Bíldudalur, 20 May 2025 Icelandic Salmon is the parent company of Arnarlax and its subsidiaries, which are involved in salmon farming and processing in Iceland. The companies are collectively referred to as "Icelandic Salmon" or the "Group". In the first quarter, Icelandic Salmon experienced biological challenges at sea. To protect animal welfare, some volumes were harvested early at low average weights. Results were marked by mortality-related costs, low harvest volumes, and a weaker market due to increase ...

Aalberts today reports that it has repurchased 2,500 of its own shares in the period from 12 May 2025, up to and including 16 May 2025, for an amount of EUR 77,447.70, so at an average share price of EUR 30.98. This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be cancelled following repurchase. Up to ...

Core Insights - Basilea Pharmaceutica Ltd has announced the commercial availability of its antibiotic Zevtera in the United States through its partner Innoviva Specialty Therapeutics, marking a significant milestone for the brand [1][2] - Zevtera is the first MRSA-active antibiotic approved for Staphylococcus aureus bacteremia in the US in over a decade, addressing a high medical need for treatments targeting Staphylococcus aureus infections [2][3] - The partnership with Innoviva includes a tiered royalty structure for Basilea, with potential sales milestones of up to USD 223 million [2][3] Company Overview - Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company focused on developing innovative drugs for severe bacterial and fungal infections [1][15] - The company has successfully launched two hospital brands, including Zevtera for bacterial infections and Cresemba for invasive fungal infections [15][16] - Basilea is listed on the SIX Swiss Exchange [16] Product Details - Zevtera (ceftobiprole medocaril) is an advanced-generation cephalosporin antibiotic indicated for the treatment of Staphylococcus aureus bacteremia, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia [1][3] - The drug has rapid bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria, including methicillin-resistant strains [3][12] - In the US, Zevtera is approved for use in both adult and pediatric patients aged 3 months to less than 18 years [1][3] Market Context - The introduction of Zevtera addresses the growing concern of drug-resistant pathogens, particularly in hospital settings [2][3] - Staphylococcus aureus bacteremia is associated with a 30-day all-cause mortality rate of around 20%, highlighting the urgent need for improved therapies [11] - Acute bacterial skin and skin structure infections are common in healthcare settings, with Staphylococcus aureus being the most prevalent pathogen [12]

Group 1 - The net asset value (NAV) of EfTEN United Property Fund units was 11.53 euros at the end of April, reflecting a monthly increase of 1.6% [1] - The fund reported a net profit of 449 thousand euros in April and a total net profit of 1.15 million euros for the first four months of 2025, compared to 331 thousand euros during the same period last year [1] - If the investment in EfTEN Real Estate Fund AS shares were recorded at its NAV, the NAV would be 11.58 euros, indicating a 1.4% monthly increase [1] Group 2 - The fund's largest profit in April came from its investment in Invego Uus-Järveküla OÜ, amounting to 274 thousand euros, with the company earning a total profit of 342 thousand euros from the transfer of terraced houses [2] - The next stage of the development, consisting of 17 terraced houses, is expected to be completed in June 2025, with 14 of the houses already booked by clients [2] Group 3 - The cash balance of EfTEN United Property Fund increased by 1.582 million euros in April, which included loan payments and interest from Invego Uus-Järveküla OÜ totaling 1.5 million euros and dividend receipts of 277 thousand euros [3] - The fund will distribute its largest income in history on May 29, amounting to 1.416 million euros, or 57 euro cents per fund unit [3]

Core Viewpoint - The collaboration between Biotalys and AgroFresh aims to develop sustainable biological fungicides to reduce food waste and enhance the freshness of produce, addressing the significant issue of post-harvest losses, which are estimated at 14% globally [1][2]. Group 1: Company Overview - Biotalys is an AgTech company focused on developing protein-based biocontrol solutions for sustainable crop protection, utilizing its AGROBODY™ technology platform [6][7]. - AgroFresh is a leader in post-harvest quality and freshness solutions, with over 40 years of experience in enhancing the shelf-life of fresh produce and reducing food loss [5]. Group 2: Market Context - The global post-harvest fungicide market is valued at $300 million, indicating a significant opportunity for Biotalys to expand its presence in this critical segment [3][4]. - Fungal decay poses a major challenge in the post-harvest supply chain, making effective disease management essential as fresh produce becomes more susceptible to spoilage after harvest [2]. Group 3: Collaboration Goals - The partnership between Biotalys and AgroFresh aims to innovate and provide environmentally friendly biological solutions that meet the evolving needs of global markets, ultimately helping to reduce food waste [3][2]. - The collaboration is expected to enhance the innovation pipeline of AgroFresh, introducing novel technologies that preserve freshness and support produce suppliers [2].

Company Overview - SalMar ASA is one of the world's largest and most efficient producers of salmon, with farming operations in Central Norway, Northern Norway, Offshore, and Iceland, as well as significant harvesting and secondary processing operations [9] - The company owns 50% of Scottish Sea Farms Ltd, further enhancing its market presence [9] Recent Developments - SalMar has completed the purchase of a controlling stake in AS Knutshaugfisk, which has 3,466 tons MTB in licenses and four farming locations in Central Norway [2] - A merger plan between Wilsgård AS and SalMar Farming AS has been approved, with SalMar holding a 37.5% stake in Wilsgård. This merger is expected to enhance operational efficiency and financial robustness [3][4] Financial Performance - In Q1 2025, SalMar reported an operational EBIT of NOK 798 million with a harvest volume of 42,700 tonnes, resulting in an operational EBIT per kg of NOK 18.7 [7] - The harvest volume for Norway was 40,400 tonnes, with an operational EBIT of NOK 852 million, translating to NOK 21.1 per kg [7] - The first quarter was characterized by low harvest volumes, primarily due to late harvesting and fish welfare considerations, leading to a high share of downgraded fish and negatively impacting price achievement [7] Future Outlook - For 2025, SalMar expects a total harvest volume of 294,000 tonnes, representing a 17% growth compared to 2024, with specific contributions from Norway, SalMar Ocean, Iceland, and Scottish Sea Farms [5] - The company anticipates strong demand for its products despite global market uncertainties and expects lower global supply growth in the latter half of 2025 [6]

Core Insights - GlobalFoundries (GF) has signed a Memorandum of Understanding (MOU) with the Agency for Science, Technology and Research (A*STAR) to enhance its advanced packaging capabilities in Singapore [1][3] - The collaboration aims to address the growing demand for advanced packaging in the semiconductor industry, driven by applications in artificial intelligence (AI) and data-intensive technologies [2][4] - A*STAR will provide GF with access to R&D facilities and technical support, while GF will supply critical equipment to A*STAR, facilitating mutual growth in advanced packaging technologies [3][5] Company Developments - The partnership will enable skills enhancement initiatives for GF employees, focusing on developing expertise in advanced packaging [4][6] - This collaboration aligns with GF's global advanced packaging roadmap and its commitment to producing energy-efficient chips essential for AI applications [4][6] - GF's strategic roadmap includes the establishment of an Advanced Packaging and Photonics Center in New York, complementing the efforts in Singapore [6] Industry Context - Advanced packaging is a key R&D priority for the semiconductor industry, essential for delivering compact, high-performance, and energy-efficient solutions [2] - Singapore is positioning itself as a critical node in the global semiconductor supply chain, emphasizing the importance of R&D collaboration between public research and industry [5][6] - The partnership reflects a broader trend of nurturing high technology talent and continuous upskilling in response to evolving industry needs [4][5]

Core Viewpoint - Ryman Hospitality Properties, Inc. has announced an upsized public offering of common stock to fund a portion of the acquisition of JW Marriott Phoenix Desert Ridge Resort & Spa, with the offering size increased from 2.3 million shares to 2.6 million shares at a price of $96.20 per share [1][2]. Group 1: Offering Details - The offering will consist of 2,600,000 shares of common stock, with an additional 30-day option for underwriters to purchase up to 390,000 more shares [1]. - The expected closing date for the offering is around May 21, 2025, subject to customary closing conditions [1]. - The offering is being conducted under the Company's shelf registration statement on Form S-3, which became effective on June 5, 2023 [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be contributed to RHP Hotel Properties, LP, and will primarily fund a portion of the approximately $865 million purchase price for the Desert Ridge Acquisition [2]. - Any remaining funds from the offering will be allocated for general corporate purposes if the Desert Ridge Acquisition does not close [2]. Group 3: Underwriters - Morgan Stanley, BofA Securities, J.P. Morgan, and Wells Fargo Securities are acting as active joint book-running managers for the offering [3]. - Other bookrunners include Deutsche Bank Securities, BTIG, Credit Agricole CIB, Scotiabank, SMBC Nikko, and Raymond James [3]. Group 4: Company Overview - Ryman Hospitality Properties, Inc. is a leading lodging and hospitality real estate investment trust specializing in upscale convention center resorts and entertainment experiences [6]. - The Company owns several major properties, including Gaylord Opryland Resort & Convention Center and JW Marriott San Antonio Hill Country Resort & Spa, totaling 11,414 rooms and over 3 million square feet of meeting space [6][7].

Core Viewpoint - Mainz Biomed N.V. has announced a follow-on offering of 2,000,000 units at an effective price of $2.00 per unit, aiming for gross proceeds of approximately $4.0 million [1] Group 1: Offering Details - Each unit in the offering consists of one ordinary share (or pre-funded warrant), one Series A warrant, and one Series B warrant [1] - The Series A and Series B warrants are immediately exercisable at an exercise price of $2.00 per share, with Series A expiring in five years and Series B expiring either 30 days after results from the eAArly Detect 2 study or one year from issuance [1] - The offering is expected to close on or about May 21, 2025, subject to customary closing conditions [2] Group 2: Warrant Amendment Agreement - The company has entered into a Warrant Amendment Agreement to reduce the effective strike price of previously issued Series A and Series B Warrants from December 12, 2024, to an amended exercise price of $2.00 [3] Group 3: Regulatory Information - The newly issued securities are being offered under a registration statement on Form F-1, which was declared effective by the SEC on May 16, 2025 [4] - A final prospectus related to the offering will be filed with the SEC, and copies can be obtained from Maxim Group LLC [4] Group 4: Company Overview - Mainz Biomed specializes in molecular genetic diagnostic solutions for early cancer detection, with its flagship product being ColoAlert®, a non-invasive test for colorectal cancer marketed in Europe [5] - The company is conducting a clinical study to prepare for its pivotal FDA clinical study and US regulatory approval [5] - Mainz Biomed's product portfolio also includes PancAlert, an early-stage pancreatic cancer screening test [5]

Core Insights - PrimeEnergy Resources Corporation reported a 16.4% year-over-year increase in revenue for Q1 2025, driven by growth in oil and gas production [1][6] - Despite a decline in earnings per share compared to Q1 2024, the company emphasized significant shareholder returns and operational momentum [1][4] Financial Performance - Revenue reached $50.1 million, up 16.4% from the previous year [6] - Oil production increased to 457,000 barrels, a rise of 6.0% [6] - Natural gas production surged to 2.39 billion cubic feet (Bcf), marking a 106.6% increase [6] - NGL (Natural Gas Liquids) production rose to 454,000 barrels, up 120.4% [6] - Net income was reported at $9.1 million, a decrease of 19.3% [6] - Diluted earnings per share (EPS) fell to $3.72, down 15.7% [6] Shareholder Returns - The company has returned a total of $112.6 million to shareholders through stock repurchases since initiating its buyback program [3] - In 2025, 47,970 shares were repurchased at a cost of $9.17 million [6] - As of May 19, 2025, the outstanding share count was 2,428,000, including vested options [3] Operational Highlights - The CFO highlighted strong operational momentum with significant growth in natural gas and NGL volumes [4] - Total assets increased to $339.3 million at the end of the quarter, up from $324.6 million as of December 31, 2024 [3]